Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.51 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.46 |
| ▸ | GAA | P10253 | 4/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | STAT1 | P42224 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29514133 | 1.00 | MAPT (0.51) | MAPTKMT2AKDM4EGRM4ALDH1A1 | |
| SCHEMBL12235984 | 0.87 | MAPT (0.51) | MAPTKMT2AKDM4EALDH1A1GAA | |
| SCHEMBL1887021 | 0.86 | MAPT (0.67) | MAPTKMT2AKDM4EALDH1A1GAA | |
| SCHEMBL17560320 | 0.83 | GRM4 (0.51) | MAPTKMT2AKDM4EGRM4ALDH1A1 | |
| SCHEMBL19661750 | 0.83 | GRM4 (0.58) | MAPTKMT2AGRM4ALDH1A1MEN1 | |
| SCHEMBL13284887 | 0.83 | GRM4 (0.51) | MAPTKMT2AKDM4EGRM4ALDH1A1 | |
| SCHEMBL31470500 | 0.83 | ALDH1A1 (0.44) | MAPTKMT2AKDM4EGRM4ALDH1A1 | |
| SCHEMBL8680075 | 0.81 | KMT2A (0.53) | MAPTKMT2AKDM4EALDH1A1GAA | |
| SCHEMBL5038742 | 0.80 | ALDH1A1 (0.56) | MAPTKMT2AKDM4EGRM4ALDH1A1 | |
| SCHEMBL15972268 | 0.78 | GRM4 (0.59) | MAPTKMT2AGRM4ALDH1A1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240043420-A1 | 7-AZAINDOLE COMPOUNDS FOR INHIBITION OF BCR-ABL TYROSINE KINASES | ENLIVEN INC. | 2024-02-08 | — | — | US | disclosed |
| US-20230382907-A1 | 5- AND 6-AZAINDOLE COMPOUNDS FOR INHIBITION OF BCR-ABL TYROSINE KINASES | ENLIVEN INC. | 2023-11-30 | — | — | US | disclosed |
| US-11807638-B2 | 5- and 6-azaindole compounds for inhibition of Bcr-Abl tyrosine kinases | ENLIVEN INC. (US) | 2023-11-07 | — | — | US | disclosed |
| US-11767321-B2 | 5- and 6-azaindole compounds for inhibition of BCR-ABL tyrosine kinases | ENLIVEN INC. (US) | 2023-09-26 | — | — | US | disclosed |
| EP-4225741-A1 | 7-AZAINDOLE COMPOUNDS FOR INHIBITION OF BCR-ABL TYROSINE KINASES | Enliven Therapeutics, Inc. (US) | 2023-08-16 | — | — | EP | disclosed |
| CN-116438182-A | 7-azaindole compounds for inhibiting BCR-ABL tyrosine kinase | 活力疗法公司 | 2023-07-14 | — | — | CN | disclosed |
| US-20230130724-A1 | 5- AND 6-AZAINDOLE COMPOUNDS FOR INHIBITION OF BCR-ABL TYROSINE KINASES | ENLIVEN INC. | 2023-04-27 | — | — | US | disclosed |
| WO-2022076973-A1 | 7-AZAINDOLE COMPOUNDS FOR INHIBITION OF BCR-ABL TYROSINE KINASES | ENLIVEN THERAPEUTICS, INC. (US) | 2022-04-14 | — | — | WO | disclosed |
| WO-2022076975-A1 | 5- AND 6-AZAINDOLE COMPOUNDS FOR INHIBITION OF BCR-ABL TYROSINE KINASES | ENLIVEN THERAPEUTICS, INC. (US) | 2022-04-14 | — | — | WO | disclosed |
| US-8957219-B2 | Acetic acid amide derivative having inhibitory activity on endothelial lipase | SHIONOGI & CO., LTD. (JP) | 2015-02-17 | — | — | US | disclosed |
| US-20110251386-A1 | ACETIC ACID AMIDE DERIVATIVE HAVING INHIBITORY ACTIVITY ON ENDOTHELIAL LIPASE | SHIONOGI & CO., LTD. (JP) | 2011-10-13 | — | — | US | disclosed |
| EP-2351744-A1 | ACETIC ACID AMIDE DERIVATIVE HAVING INHIBITORY ACTIVITY ON VASCULAR ENDOTHELIAL LIPASE | Shionogi & Co., Ltd. (JP) | 2011-08-03 | — | — | EP | disclosed |
| US-7923450-B2 | Modulators for amyloid beta | HOFFMANN-LA ROCHE INC. (US) | 2011-04-12 | — | — | US | disclosed |
| US-20110015175-A1 | Bicyclic Compounds for the Reduction of Beta-Amyloid Production | BRISTOL-MYERS SQUIBB COMPANY | 2011-01-20 | — | — | US | disclosed |
| US-20110015175-A1 | Bicyclic Compounds for the Reduction of Beta-Amyloid Production | BRISTOL-MYERS SQUIBB COMPANY | 2011-01-20 | — | — | US | disclosed |
| US-20110015175-A1 | Bicyclic Compounds for the Reduction of Beta-Amyloid Production | BRISTOL-MYERS SQUIBB COMPANY | 2011-01-20 | — | — | US | disclosed |
| EP-2231629-A1 | MODULATORS FOR AMYLOID BETA | F. Hoffmann-La Roche AG (CH) | 2010-09-29 | — | — | EP | disclosed |
| WO-2010083141-A1 | BICYCLIC COMPOUNDS FOR THE REDUCTION OF BETA-AMYLOID PRODUCTION | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-07-22 | — | — | WO | disclosed |
| WO-2009087127-A1 | MODULATORS FOR AMYLOID BETA | F. HOFFMANN-LA ROCHE AG (CH) | 2009-07-16 | — | — | WO | disclosed |
| US-20090181965-A1 | MODULATORS FOR AMYLOID BETA | F. HOFFMANN-LA ROCHE AG (CH) | 2009-07-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110251386-A1 | ACETIC ACID AMIDE DERIVATIVE HAVING INHIBITORY ACTIVITY ON ENDOTHELIAL LIPASE | LIPG, CEL, LIPA | MAPT 4843/4885KMT2A 2645/4885KDM4E 1810/4885 |
| US-11807638-B2 | 5- and 6-azaindole compounds for inhibition of Bcr-Abl tyrosine kinases | ABL1, ABL2, BCR | MAPT 4157/4885KMT2A 450/4885KDM4E 438/4885 |
| US-20230382907-A1 | 5- AND 6-AZAINDOLE COMPOUNDS FOR INHIBITION OF BCR-ABL TYROSINE KINASES | ABL1, ABL2, BCR | MAPT 4157/4885KMT2A 450/4885KDM4E 438/4885 |
| US-11767321-B2 | 5- and 6-azaindole compounds for inhibition of BCR-ABL tyrosine kinases | ABL1, ABL2, BCR | MAPT 4157/4885KMT2A 450/4885KDM4E 438/4885 |
| US-20240043420-A1 | 7-AZAINDOLE COMPOUNDS FOR INHIBITION OF BCR-ABL TYROSINE KINASES | ABL1, ABL2, BCR | MAPT 4135/4885KMT2A 411/4885KDM4E 476/4885 |
| US-20230130724-A1 | 5- AND 6-AZAINDOLE COMPOUNDS FOR INHIBITION OF BCR-ABL TYROSINE KINASES | ABL1, ABL2, BCR | MAPT 4157/4885KMT2A 450/4885KDM4E 438/4885 |
| US-20090181965-A1 | MODULATORS FOR AMYLOID BETA | APP, PSEN1, BACE1 | MAPT 26/4885KMT2A 2297/4885KDM4E 4361/4885 |
| US-20110015175-A1 | Bicyclic Compounds for the Reduction of Beta-Amyloid Production | APP, BACE1, APBA1 | MAPT 15/4885KMT2A 4488/4885KDM4E 4459/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.